What are the responsibilities and job description for the DMPK Scientist position at Arvinas?
Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.
Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-102, targeting LRRK2 for neurodegenerative diseases; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic, colorectal, and non-small cell lung cancers; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER /HER2- breast cancer.
On August 8th 2025, the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER ), human epidermal growth factor receptor 2–negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant.
In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024.
#TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say.
Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, please visit www.arvinas.com and connect on LinkedIn and X.
Position Summary
We have an exciting opening for an experienced DMPK scientist. The incumbent will contribute as a DMPK scientist on project teams from drug discovery through all stages of drug development, with a scientific background on key aspects of DMPK science, including but not limited to in vitro and in vivo ADME, animal PK, toxicokinetics, drug metabolism, DME- and transporter-based DDI, 14C-ADME studies, QWBA, human PK prediction.
This position reports to the Head of Nonclinical Sciences and may be based at our headquarter location in New Haven, CT or a remote role based within the U.S.
Principal Responsibilities
Key responsibilities of this role include, but are not limited to:
Arvinas is an equal opportunity employer. All qualified applicants will be considered for employment without regard to race, color, religion, sex, sexual orientation, gender identify, national origin, disability or protected veteran status.
Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-102, targeting LRRK2 for neurodegenerative diseases; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic, colorectal, and non-small cell lung cancers; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER /HER2- breast cancer.
On August 8th 2025, the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER ), human epidermal growth factor receptor 2–negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant.
In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024.
#TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say.
Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, please visit www.arvinas.com and connect on LinkedIn and X.
Position Summary
We have an exciting opening for an experienced DMPK scientist. The incumbent will contribute as a DMPK scientist on project teams from drug discovery through all stages of drug development, with a scientific background on key aspects of DMPK science, including but not limited to in vitro and in vivo ADME, animal PK, toxicokinetics, drug metabolism, DME- and transporter-based DDI, 14C-ADME studies, QWBA, human PK prediction.
This position reports to the Head of Nonclinical Sciences and may be based at our headquarter location in New Haven, CT or a remote role based within the U.S.
Principal Responsibilities
Key responsibilities of this role include, but are not limited to:
- Serve as a project DMPK scientist and advise discovery teams on strategies for early ADMET profiling up to the selection of lead candidate into preclinical development.
- Represent DMPK function on company-wide development teams to support the advancement of preclinical and clinical development assets.
- Contribute to the in vitro DDI and other in vitro/in vivo DMPK assessment for individual preclinical drug candidates and ensure timely availability of key data as part of the IND enabling activities.
- Recommend stage appropriate clinical DDI strategy to the clinical pharmacology function.
- Contribute to outsource of DMPK studies and ensure timely and high quality conduct of in vitro and in vivo ADMET studies. Partner with key CROs to develop and customize ADMET assays to support PROTAC drug discovery and development.
- Contribute to the preparation of DMPK component of regulatory documents such as IND, IB, or other documents.
- Stay up to date with the scientific advance and regulatory landscape for DMPK science in drug discovery and development
- In-depth knowledge or expertise on one or several aspects of DMPK science in drug discovery and/or development, such as biotransformation, bioanalysis, pharmacokinetics, toxicokinetics, DME- and transporter-based drug-drug interaction, PBPK or PK/PD modeling, human PK prediction.
- General knowledge of drug discovery and development process.
- Experience in representing DMPK function on discovery and development teams.
- Ability to integrate DMPK knowledge of individual drugs and prepare DMPK components of regulatory documents.
- Hands-on experience and proficiency in PK analysis with PK or modeling software such as Phoenix.
- Knowledge of relevant regulatory guidance in areas such as drug-drug interaction, bioanalysis, and GLP.
- Arvinas will not be providing VISA sponsorship for this position. You must have the ability to work without a need for a current or future VISA sponsorship.
- The duties of this role are generally conducted in a combination of lab and home office environments. Employees must be able, with or without an accommodation to lift/carry 15/30 pounds unassisted/assisted; work comfortable in a controlled environment with and around biological, infectious and hazardous materials; gown/degown PPE; use a computer; engage in communications via phone, video, and electronic messaging; engage in problem solving, analysis and dialogue; collaborate with others; maintain general availability during standard business hours.
- Ph.D. in pharmaceutical science, chemistry, biochemistry, or related scientific discipline with ten-plus years of relevant experience in DMPK in the biopharmaceutical industry or CROs supporting pharmaceutical development, preferably with a focus on small molecules.
- Direct experience with PROTAC, molecular glue, or ADC highly desirable.
Arvinas is an equal opportunity employer. All qualified applicants will be considered for employment without regard to race, color, religion, sex, sexual orientation, gender identify, national origin, disability or protected veteran status.